ArticleInternational journal of particle therapy2026
Clinical White Paper From the "Hadrontherapy for Life" Symposium-Clinical Expansion of Carbon Ion Facilities Worldwide.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbon ion radiotherapy (CIRT) combines the physical precision of charged particles with high-linear energy transfer (LET) biological effectiveness, enabling superior control of radioresistant or anatomically complex tumors. Initially developed in Japan, CIRT is slowly expanding globally with increasing institutional and clinical maturity. Objective: To summarize current clinical evidence, operational strategies, and expansion plans for carbon ion facilities worldwide, as discussed during the "Hadrontherapy-for-Life" symposium held in Caen, France (March 2025). Methods: This white paper compiles presentations and institutional reports from major CIRT centers in Japan (QST, Gunma), Europe (HIT, CNAO, MedAustron, Cyclhad), and other emerging sites. Data sources include institutional registries, peer-reviewed studies, and national frameworks for hadrontherapy development. Results: Over 50,000 patients have received CIRT worldwide. Japan remains the leading contributor through the J-CROS network, emphasizing registry-based research, hypofractionation, and treatment of mobile tumors. European centers adopt translational programs aimed at further exploiting biological properties of carbon and helium ions. Major barriers include heterogeneous dose-modeling (local effect model vs modified microdosimetric kinetic model), limited image guidance, lack of standardized indications, and funding disparities. Ongoing efforts emphasize registry harmonization, pragmatic trials, and cost-effectiveness modeling. New multi-ion facilities such as Cyclhad (Caen) aim to propose multi-ion therapy, increase the level of evidence for clinical use, and promote research. Conclusions: CIRT is transitioning from pioneering programs to a coordinated global network. Collaborative initiatives and shared data platforms are essential to establish evidence-based indications, optimize biological modeling, and ensure economic sustainability. The "Hadrontherapy-for-Life" initiative calls for a strategic step toward internationally standardized, clinically integrated heavy-ion therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.